Provides undergone several preclinical tests which have verified its principle of action.

AFFiRiS AG develops PD01 vaccine for Parkinson’s disease Today AFFiRiS AG announced a significant step of progress in the advancement of it is vaccine for Parkinson’s disease suhagra . The vaccine, known as PD01, provides undergone several preclinical tests which have verified its principle of action . The organization is now starting to prepare for clinical trials of the vaccine which are planned to commence at the start of 2011. Due to a completely innovative effect strategy this vaccine could for the very first time present a chance of treating the causes of Parkinson’s disease. The foundation of PD01 is the company’s AFFITOM technology, which two vaccines for Alzheimer’s disease are structured that have already effectively completed their initial scientific studies.